Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
149
0
20

Year Published

2008
2008
2017
2017

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 208 publications
(170 citation statements)
references
References 108 publications
(89 reference statements)
1
149
0
20
Order By: Relevance
“…Interstitial pneumonitis has been recognised as being associated with sustained treatment with rapamycin and other rapamycin derivatives (Pham et al, 2004;El-Maraghi et al, 2006). Pulmonary toxicity is a potential toxicity associated with the use of newer anti-neoplastic agents (Vahid and Marik, 2008). In this study, interstitial pneumonitis was of short duration and recovered under corticosteroid therapy.…”
Section: Discussionmentioning
confidence: 66%
“…Interstitial pneumonitis has been recognised as being associated with sustained treatment with rapamycin and other rapamycin derivatives (Pham et al, 2004;El-Maraghi et al, 2006). Pulmonary toxicity is a potential toxicity associated with the use of newer anti-neoplastic agents (Vahid and Marik, 2008). In this study, interstitial pneumonitis was of short duration and recovered under corticosteroid therapy.…”
Section: Discussionmentioning
confidence: 66%
“…Nevertheless, most tumour types are only marginally sensitive to mTORC1 inhibitors either because of redundant signal transduction pathways, lack of functional apoptosis/autophagy, or expression of VEGF/VEGFR-independent angiogenesis. Furthermore, although acute toxicity of rapalogues is fairly acceptable, long-term exposure to several rapalogues is associated with interstitial pneumonitis (Vahid and Marik, 2008) that may require treatment discontinuation and jeopardise efficacy. It is thus important to consider other drugs blocking the mTOR signalling pathways by different mechanisms of action with distinct toxicity and overcoming current mechanisms of resistance to rapalogues.…”
Section: 'Non-rapalogues' Mtor Kinase Inhibitorsmentioning
confidence: 99%
“…The incidence of trastuzumab-induced pneumonitis has been reported in the literature as 0.4-0.6%. [19] Of our patients 97.5% including this restrictive patient had been given taxancontaining regimen although this regimen was not found efficient on PFTs in our study. Paclitaxel cause There are some limitations of this study.…”
Section: Discussionmentioning
confidence: 54%